{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T22:24:54Z","timestamp":1794522294775,"version":"4.9.1"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T00:00:00Z","timestamp":1763510400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001843","name":"DST | Science and Engineering Research Board","doi-asserted-by":"publisher","award":["IPA\/2020\/000168"],"award-info":[{"award-number":["IPA\/2020\/000168"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-033578"],"award-info":[{"award-number":["INV-033578"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-030592"],"award-info":[{"award-number":["INV-030592"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-042471"],"award-info":[{"award-number":["INV-042471"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>SARS-CoV-2 Spike - the sole neutralization target, is highly resilient to the immune pressure driving genetic evolution. While potency and breadth of neutralization are widely studied, the incomplete neutralization - the mechanism of resistance without needing genetic change - remains unexplored. Several monoclonal antibodies, although potent, showed incomplete neutralization of genetically homogeneous pseudovirus suggesting the existence of distinct spike conformations. The residual infectivity at high antibody concentration indicates a viral fraction with intrinsic resistance to the antibody. Although the published studies on spike glycosylation, structure, and conformations provide evidence of spike heterogeneity the precise mechanism for the incomplete neutralization has not been established. In this study, we devise a method to separate the un-neutralized virion population, called as persistent fraction of infectivity (PF), and characterize the viral spike protein. The neutralization resistance of PF is stable and unrelated to the conformational equilibrium that exists in the pseudovirus stock. The spike on the PF is highly cleaved between S1 and S2, adopts the closed conformation, and express more mannosidic glycans on RBD than the total virus population. Our study provides possible explanations for the incomplete neutralization by antibodies and delineates the association between furin cleavage of spike, its conformation and glycosylation.<\/jats:p>","DOI":"10.1038\/s41467-025-65099-y","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T12:18:25Z","timestamp":1763554705000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Spike conformational and glycan heterogeneity associated with furin cleavage causes incomplete neutralization of SARS-CoV-2"],"prefix":"10.1038","volume":"16","author":[{"given":"Sahil","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rathina","family":"Delipan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanchal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Jadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kawkab","family":"Kanjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randhir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raju","family":"Rajmani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suprit","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4500-2133","authenticated-orcid":false,"given":"Krishan G.","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayanta","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2324-8573","authenticated-orcid":false,"given":"Rogier W.","family":"Sanders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3422-8161","authenticated-orcid":false,"given":"Marit J.","family":"van Gils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0823-7577","authenticated-orcid":false,"given":"Raghavan","family":"Varadarajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh P.","family":"Ringe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,19]]},"reference":[{"key":"65099_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/s41586-020-2349-y","volume":"583","author":"D Pinto","year":"2020","unstructured":"Pinto, D. et al. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 583, 290\u2013295 (2020).","journal-title":"Nature"},{"key":"65099_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1126\/science.abf4830","volume":"371","author":"CG Rappazzo","year":"2021","unstructured":"Rappazzo, C. G. et al. Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody. Science 371, 823\u2013829 (2021).","journal-title":"Science"},{"key":"65099_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37826-w","volume":"14","author":"M Ragonnet-Cronin","year":"2023","unstructured":"Ragonnet-Cronin, M. et al. Generation of SARS-CoV-2 escape mutations by monoclonal antibody therapy. Nat. Commun. 14, 3334 (2023).","journal-title":"Nat. Commun."},{"key":"65099_CR4","unstructured":"Tonkin-Hill, G. et al. Patterns of within-host genetic diversity in SARS-CoV-2. Elife 10, e66857 (2021)."},{"key":"65099_CR5","doi-asserted-by":"crossref","unstructured":"El Moussaoui, M. et al. Intrahost evolution leading to distinct lineages in the upper and lower respiratory tracts during SARS-CoV-2 prolonged infection. Virus Evol. 10, veae073 (2024).","DOI":"10.1093\/ve\/veae073"},{"key":"65099_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41586-021-03291-y","volume":"592","author":"SA Kemp","year":"2021","unstructured":"Kemp, S. A. et al. SARS-CoV-2 evolution during treatment of chronic infection. Nature 592, 277\u2013282 (2021).","journal-title":"Nature"},{"key":"65099_CR7","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1038\/s41591-022-02138-x","volume":"29","author":"ST Tan","year":"2023","unstructured":"Tan, S. T. et al. Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave. Nat. Med. 29, 358\u2013365 (2023).","journal-title":"Nat. Med."},{"key":"65099_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3201\/eid2802.211789","volume":"28","author":"I Kislaya","year":"2022","unstructured":"Kislaya, I. et al. Comparative effectiveness of coronavirus vaccine in preventing breakthrough infections among vaccinated persons infected with delta and alpha variants. Emerg. Infect. Dis. 28, 331\u2013337 (2022).","journal-title":"Emerg. Infect. Dis."},{"key":"65099_CR9","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.ajpath.2021.10.019","volume":"192","author":"PA Christensen","year":"2022","unstructured":"Christensen, P. A. et al. Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas. Am. J. Pathol. 192, 320\u2013331 (2022).","journal-title":"Am. J. Pathol."},{"key":"65099_CR10","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/S0140-6736(22)02465-5","volume":"401","author":"C-F Team","year":"2023","unstructured":"Team, C.-F. Past SARS-CoV-2 infection protection against re-infection: a systematic review and meta-analysis. Lancet 401, 833\u2013842 (2023).","journal-title":"Lancet"},{"key":"65099_CR11","doi-asserted-by":"publisher","first-page":"e1011601","DOI":"10.1371\/journal.ppat.1011601","volume":"19","author":"RP Ringe","year":"2023","unstructured":"Ringe, R. P. et al. Glycan heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. PLoS Pathog. 19, e1011601 (2023).","journal-title":"PLoS Pathog."},{"key":"65099_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-023-00624-9","volume":"20","author":"P Colin","year":"2023","unstructured":"Colin, P. et al. Conformational antigenic heterogeneity as a cause of the persistent fraction in HIV-1 neutralization. Retrovirology 20, 9 (2023).","journal-title":"Retrovirology"},{"key":"65099_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.698944","volume":"12","author":"R Lassauniere","year":"2021","unstructured":"Lassauniere, R. et al. In vitro characterization of fitness and convalescent antibody neutralization of SARS-CoV-2 cluster 5 variant emerging in mink at Danish Farms. Front Microbiol 12, 698944 (2021).","journal-title":"Front Microbiol"},{"key":"65099_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-10897-4","volume":"10","author":"H Zhou","year":"2019","unstructured":"Zhou, H. et al. Structural definition of a neutralization epitope on the N-terminal domain of MERS-CoV spike glycoprotein. Nat. Commun. 10, 3068 (2019).","journal-title":"Nat. Commun."},{"key":"65099_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103944","volume":"78","author":"T Tada","year":"2022","unstructured":"Tada, T. et al. Increased resistance of SARS-CoV-2 Omicron variant to neutralization by vaccine-elicited and therapeutic antibodies. EBioMedicine 78, 103944 (2022).","journal-title":"EBioMedicine"},{"key":"65099_CR16","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.chom.2020.11.001","volume":"28","author":"M Lu","year":"2020","unstructured":"Lu, M. et al. Real-time conformational dynamics of SARS-CoV-2 spikes on virus particles. Cell Host Microbe 28, 880\u2013891 (2020).","journal-title":"Cell Host Microbe"},{"key":"65099_CR17","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1038\/s41586-021-04005-0","volume":"600","author":"F Schmidt","year":"2021","unstructured":"Schmidt, F. et al. High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. Nature 600, 512\u2013516 (2021).","journal-title":"Nature"},{"key":"65099_CR18","doi-asserted-by":"crossref","unstructured":"Andreano, E. et al. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma. Proc. Natl. Acad. Sci. USA 118, e2103154118 (2021).","DOI":"10.1073\/pnas.2103154118"},{"key":"65099_CR19","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/s41586-024-07029-4","volume":"626","author":"M Ghafari","year":"2024","unstructured":"Ghafari, M. et al. Prevalence of persistent SARS-CoV-2 in a large community surveillance study. Nature 626, 1094\u20131101 (2024).","journal-title":"Nature"},{"key":"65099_CR20","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1126\/science.abb2507","volume":"367","author":"D Wrapp","year":"2020","unstructured":"Wrapp, D. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 367, 1260\u20131263 (2020).","journal-title":"Science"},{"key":"65099_CR21","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1016\/j.molcel.2022.03.028","volume":"82","author":"SM Gobeil","year":"2022","unstructured":"Gobeil, S. M. et al. Structural diversity of the SARS-CoV-2 Omicron spike. Mol. Cell 82, 2050\u20132068 (2022).","journal-title":"Mol. Cell"},{"key":"65099_CR22","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41594-020-0479-4","volume":"27","author":"R Henderson","year":"2020","unstructured":"Henderson, R. et al. Controlling the SARS-CoV-2 spike glycoprotein conformation. Nat. Struct. Mol. Biol. 27, 925\u2013933 (2020).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"65099_CR23","doi-asserted-by":"crossref","unstructured":"Gobeil, S. M. et al. Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science 373, eabi6226 (2021).","DOI":"10.1126\/science.abi6226"},{"key":"65099_CR24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41586-020-2772-0","volume":"588","author":"DJ Benton","year":"2020","unstructured":"Benton, D. J. et al. Receptor binding and priming of the spike protein of SARS-CoV-2 for membrane fusion. Nature 588, 327\u2013330 (2020).","journal-title":"Nature"},{"key":"65099_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110428","volume":"38","author":"G Cerutti","year":"2022","unstructured":"Cerutti, G. et al. Cryo-EM structure of the SARS-CoV-2 Omicron spike. Cell Rep. 38, 110428 (2022).","journal-title":"Cell Rep."},{"key":"65099_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28882-9","volume":"13","author":"G Ye","year":"2022","unstructured":"Ye, G., Liu, B. & Li, F. Cryo-EM structure of a SARS-CoV-2 omicron spike protein ectodomain. Nat. Commun. 13, 1214 (2022).","journal-title":"Nat. Commun."},{"key":"65099_CR27","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/s44318-024-00303-1","volume":"43","author":"Z Ke","year":"2024","unstructured":"Ke, Z. et al. Virion morphology and on-virus spike protein structures of diverse SARS-CoV-2 variants. EMBO J. 43, 6469\u20136495 (2024).","journal-title":"EMBO J."},{"key":"65099_CR28","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1021\/acscentsci.1c00058","volume":"7","author":"J Brun","year":"2021","unstructured":"Brun, J. et al. Assessing antigen structural integrity through glycosylation analysis of the SARS-CoV-2 viral spike. ACS Cent. Sci. 7, 586\u2013593 (2021).","journal-title":"ACS Cent. Sci."},{"key":"65099_CR29","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2213332120","volume":"120","author":"Y Song","year":"2023","unstructured":"Song, Y. et al. In situ architecture and membrane fusion of SARS-CoV-2 Delta variant. Proc. Natl. Acad. Sci. USA 120, e2213332120 (2023).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65099_CR30","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01672-23","volume":"15","author":"F Zhang","year":"2024","unstructured":"Zhang, F. et al. SARS-CoV-2 spike glycosylation affects function and neutralization sensitivity. mBio 15, e0167223 (2024).","journal-title":"mBio"},{"key":"65099_CR31","first-page":"367","volume":"14","author":"CH Andrewes","year":"1993","unstructured":"Andrewes, C. H. & Elford, W. J. Observations on Anti-Phage Sera. I: \u201cThe Percentage Law\u201d. Br. J. Exp. Pathol. 14, 367\u2013376 (1993).","journal-title":"Br. J. Exp. Pathol."},{"key":"65099_CR32","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1038\/s41589-022-01060-0","volume":"18","author":"B Khatri","year":"2022","unstructured":"Khatri, B. et al. A dimeric proteomimetic prevents SARS-CoV-2 infection by dimerizing the spike protein. Nat. Chem. Biol. 18, 1046\u20131055 (2022).","journal-title":"Nat. Chem. Biol."},{"key":"65099_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2024.105856","volume":"225","author":"M Klevanski","year":"2024","unstructured":"Klevanski, M., Kim, H., Heilemann, M., Kuner, T. & Bartenschlager, R. Glycan-directed SARS-CoV-2 inhibition by leek extract and lectins with insights into the mode-of-action of Concanavalin A. Antivir. Res. 225, 105856 (2024).","journal-title":"Antivir. Res."},{"key":"65099_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100774","volume":"3","author":"JF Chan","year":"2022","unstructured":"Chan, J. F. et al. A molecularly engineered, broad-spectrum anti-coronavirus lectin inhibits SARS-CoV-2 and MERS-CoV infection in vivo. Cell Rep. Med. 3, 100774 (2022).","journal-title":"Cell Rep. Med."},{"key":"65099_CR35","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1126\/science.abb9983","volume":"369","author":"Y Watanabe","year":"2020","unstructured":"Watanabe, Y., Allen, J. D., Wrapp, D., McLellan, J. S. & Crispin, M. Site-specific glycan analysis of the SARS-CoV-2 spike. Science 369, 330\u2013333 (2020).","journal-title":"Science"},{"key":"65099_CR36","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1021\/acs.biochem.3c00109","volume":"62","author":"A Nangarlia","year":"2023","unstructured":"Nangarlia, A. et al. Irreversible inactivation of SARS-CoV-2 by lectin engagement with two glycan clusters on the spike protein. Biochemistry 62, 2115\u20132127 (2023).","journal-title":"Biochemistry"},{"key":"65099_CR37","doi-asserted-by":"publisher","first-page":"e1009089","DOI":"10.1371\/journal.ppat.1009089","volume":"16","author":"NC Wu","year":"2020","unstructured":"Wu, N. C. et al. A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody. PLoS Pathog. 16, e1009089 (2020).","journal-title":"PLoS Pathog."},{"key":"65099_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.576622","volume":"11","author":"L Duan","year":"2020","unstructured":"Duan, L. et al. The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: Implications for the design of spike-basedvaccine immunogens. Front. Immunol. 11, 576622 (2020).","journal-title":"Front. Immunol."},{"key":"65099_CR39","doi-asserted-by":"publisher","first-page":"e2210990119","DOI":"10.1073\/pnas.2210990119","volume":"119","author":"K Yang","year":"2022","unstructured":"Yang, K. et al. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the prehairpin intermediate of the spike protein. Proc. Natl. Acad. Sci. USA 119, e2210990119 (2022).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"65099_CR40","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.coviro.2021.08.010","volume":"50","author":"J Zhang","year":"2021","unstructured":"Zhang, J., Xiao, T., Cai, Y. & Chen, B. Structure of SARS-CoV-2 spike protein. Curr. Opin. Virol. 50, 173\u2013182 (2021).","journal-title":"Curr. Opin. Virol."},{"key":"65099_CR41","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abq8678","volume":"8","author":"Q Yang","year":"2022","unstructured":"Yang, Q. et al. Role for N-glycans and calnexin-calreticulin chaperones in SARS-CoV-2 Spike maturation and viral infectivity. Sci. Adv. 8, eabq8678 (2022).","journal-title":"Sci. Adv."},{"key":"65099_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2022.167928","volume":"435","author":"ML Newby","year":"2023","unstructured":"Newby, M. L. et al. Variations within the Glycan Shield of SARS-CoV-2 Impact Viral Spike Dynamics. J. Mol. Biol. 435, 167928 (2023).","journal-title":"J. Mol. Biol."},{"key":"65099_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2023.102619","volume":"81","author":"AG Wrobel","year":"2023","unstructured":"Wrobel, A. G. Mechanism and evolution of human ACE2 binding by SARS-CoV-2 spike. Curr. Opin. Struct. Biol. 81, 102619 (2023).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"65099_CR44","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2022.104709","volume":"25","author":"CF Tien","year":"2022","unstructured":"Tien, C. F. et al. Glycosylation and S-palmitoylation regulate SARS-CoV-2 spike protein intracellular trafficking. iScience 25, 104709 (2022).","journal-title":"iScience"},{"key":"65099_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2022.102402","volume":"75","author":"H Chawla","year":"2022","unstructured":"Chawla, H., Fadda, E. & Crispin, M. Principles of SARS-CoV-2 glycosylation. Curr. Opin. Struct. Biol. 75, 102402 (2022).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"65099_CR46","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.sbi.2017.03.008","volume":"44","author":"AJ Behrens","year":"2017","unstructured":"Behrens, A. J. & Crispin, M. Structural principles controlling HIV envelope glycosylation. Curr. Opin. Struct. Biol. 44, 125\u2013133 (2017).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"65099_CR47","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.celrep.2015.05.017","volume":"11","author":"LK Pritchard","year":"2015","unstructured":"Pritchard, L. K. et al. Structural constraints determine the glycosylation of HIV-1 envelope trimers. Cell Rep. 11, 1604\u20131613 (2015).","journal-title":"Cell Rep."},{"key":"65099_CR48","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1038\/s41564-021-00908-w","volume":"6","author":"TP Peacock","year":"2021","unstructured":"Peacock, T. P. et al. The furin cleavage site in the SARS-CoV-2 spike protein is required for transmission in ferrets. Nat. Microbiol. 6, 899\u2013909 (2021).","journal-title":"Nat. Microbiol."},{"key":"65099_CR49","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/s41586-021-03237-4","volume":"591","author":"BA Johnson","year":"2021","unstructured":"Johnson, B. A. et al. Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. Nature 591, 293\u2013299 (2021).","journal-title":"Nature"},{"key":"65099_CR50","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.molcel.2020.04.022","volume":"78","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann, M., Kleine-Weber, H. & Pohlmann, S. A multibasic cleavage site in the spike protein of SARS-CoV-2 is essential for infection of human lung cells. Mol. Cell 78, 779\u2013784 (2020).","journal-title":"Mol. Cell"},{"key":"65099_CR51","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abj5365","volume":"7","author":"TG Caniels","year":"2021","unstructured":"Caniels, T. G. et al. Emerging SARS-CoV-2 variants of concern evade humoral immune responses from infection and vaccination. Sci. Adv. 7, eabj5365 (2021).","journal-title":"Sci. Adv."},{"key":"65099_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2024.102426","volume":"87","author":"J Le Pen","year":"2024","unstructured":"Le Pen, J. & Rice, C. M. The antiviral state of the cell: lessons from SARS-CoV-2. Curr. Opin. Immunol. 87, 102426 (2024).","journal-title":"Curr. Opin. Immunol."},{"key":"65099_CR53","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adp8920","volume":"16","author":"N Lasrado","year":"2024","unstructured":"Lasrado, N. et al. SARS-CoV-2 XBB.1.5 mRNA booster vaccination elicits limited mucosal immunity. Sci. Transl. Med. 16, eadp8920 (2024).","journal-title":"Sci. Transl. Med."},{"key":"65099_CR54","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1016\/j.vaccine.2023.02.019","volume":"41","author":"G Silva Vasconcelos","year":"2023","unstructured":"Silva Vasconcelos, G. et al. Persistent SARS-COV-2 infection in vaccinated individual with three doses of COVID-19 vaccine. Vaccine 41, 1778\u20131782 (2023).","journal-title":"Vaccine"},{"key":"65099_CR55","doi-asserted-by":"publisher","first-page":"e453","DOI":"10.1016\/S1473-3099(23)00815-0","volume":"24","author":"HM Machkovech","year":"2024","unstructured":"Machkovech, H. M. et al. Persistent SARS-CoV-2 infection: significance and implications. Lancet Infect. Dis. 24, e453\u2013e462 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"65099_CR56","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.abc5902","volume":"369","author":"PJM Brouwer","year":"2020","unstructured":"Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. Science 369, 643\u2013650 (2020).","journal-title":"Science"},{"key":"65099_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108009","volume":"26","author":"D Guerra","year":"2023","unstructured":"Guerra, D. et al. Broad SARS-CoV-2 neutralization by monoclonal and bispecific antibodies derived from a Gamma-infected individual. iScience 26, 108009 (2023).","journal-title":"iScience"},{"key":"65099_CR58","doi-asserted-by":"publisher","first-page":"e1010465","DOI":"10.1371\/journal.ppat.1010465","volume":"18","author":"N Hingankar","year":"2022","unstructured":"Hingankar, N. et al. A combination of potently neutralizing monoclonal antibodies isolated from an Indian convalescent donor protects against the SARS-CoV-2 Delta variant. PLoS Pathog. 18, e1010465 (2022).","journal-title":"PLoS Pathog."},{"key":"65099_CR59","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04332-22","volume":"11","author":"S Deshpande","year":"2023","unstructured":"Deshpande, S. et al. Ancestral SARS-CoV-2-driven antibody repertoire diversity in an unvaccinated individual correlates with expanded neutralization breadth. Microbiol. Spectr. 11, e0433222 (2023).","journal-title":"Microbiol. Spectr."},{"key":"65099_CR60","unstructured":"Mast, F. D. et al. Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. Elife 10, e73027 (2021)."},{"key":"65099_CR61","doi-asserted-by":"crossref","unstructured":"Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. J. Exp. Med. 217, e20201181 (2020).","DOI":"10.1084\/jem.20201181"},{"key":"65099_CR62","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.cell.2020.11.032","volume":"183","author":"AC Walls","year":"2020","unstructured":"Walls, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 183, 1735 (2020).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65099-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65099-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:03:43Z","timestamp":1763557423000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-65099-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,19]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["65099"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-65099-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6134096\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,19]]},"assertion":[{"value":"1 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10130"}}